Evidence map›Paper›PMID 32510767›Full record

ArticleThe oncologist2020

Evaluating the Age-Based Recommendations for Long-Term Follow-Up in Breast Cancer.

Annemieke Witteveen, Linda de Munck, Catharina G M Groothuis-Oudshoorn, Gabe S Sonke, Philip M Poortmans, Liesbeth J Boersma, Marjolein L Smidt, Ingrid M H Vliegen, Maarten J IJzerman, Sabine Siesling

Open access · hybridAbstract read
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. The effectiveness of personalised surveillance and aftercare in breast cancer follow-up: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Annemieke WitteveenDepartment of Biomedical Signals and Systems / Personalized eHealth Technology, University of Twente, Enschede, The Netherlands.ORCID 0000-0001-5581-6478
Linda de MunckDepartment of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Catharina G M Groothuis-OudshoornDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands.
Gabe S SonkeDepartment of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.
Philip M PoortmansIridium Kankernetwerk, Wilrijk-Antwerp, Belgium.
Liesbeth J BoersmaDepartment of Radiation Oncology, Maastricht University Medical Center (Maastro), Maastricht, The Netherlands.
Marjolein L SmidtGROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Ingrid M H VliegenDepartment of Industrial Engineering and Innovation Sciences, Technical University Eindhoven, Eindhoven, The Netherlands.
Maarten J IJzermanDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands.
Sabine SieslingDepartment of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands.
University of Twente · NLMaastricht University Medical Centre · NLEindhoven University of Technology · NLNetherlands Comprehensive Cancer Organisation · NLThe Netherlands Cancer Institute · NLUniversity of Antwerp · BEUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAfter 5 years of annual follow-up following breast cancer, Dutch guidelines are age based: annual follow-up for women <60 years, 60-75 years biennial, and none for >75 years. We determined how the risk of recurrence corresponds to these consensus-based recommendations and to the risk of primary breast cancer in the general screening population. SUBJECTS, MATERIALS, AND

methodsWomen with early-stage breast cancer in 2003/2005 were selected from the Netherlands Cancer Registry (n = 18,568). Cumulative incidence functions were estimated for follow-up years 5-10 for locoregional recurrences (LRRs) and second primary tumors (SPs). Risks were compared with the screening population without history of breast cancer. Alternative cutoffs for age were determined by log-rank tests.

resultsThe cumulative risk for LRR/SP was lower in women <60 years (5.9%, 95% confidence interval [CI] 5.3-6.6) who are under annual follow-up than for women 60-75 (6.3%, 95% CI 5.6-7.1) receiving biennial visits. All risks were higher than the 5-year risk of a primary tumor in the screening population (ranging from 1.4% to 1.9%). Age cutoffs <50, 50-69, and > 69 revealed better risk differentiation and would provide more risk-based schedules. Still, other factors, including systemic treatments, had an even greater impact on recurrence risks.

conclusionThe current consensus-based recommendations use suboptimal age cutoffs. The proposed alternative cutoffs will lead to a more balanced risk-based follow-up and thereby more efficient allocation of resources. However, more factors should be taken into account for truly individualizing follow-up based on risk for recurrence. IMPLICATIONS FOR PRACTICE: The current age-based recommendations for breast cancer follow-up after 5 years are suboptimal and do not reflect the actual risk of recurrent disease. This results in situations in which women with higher risks actually receive less follow-up than those with a lower risk of recurrence. Alternative cutoffs could be a start toward risk-based follow-up and thereby more efficient allocation of resources. However, age, or any single risk factor, is not able to capture the risk differences and therefore is not sufficient for determining follow-up. More risk factors should be taken into account for truly individualizing follow-up based on the risk for recurrence.

Indexed as

Breast NeoplasmsChild, PreschoolFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalNetherlandsRegistriesBreast cancerLocoregional recurrenceRisk-based follow-upSecond primaryThresholds

Identifiers

PMID32510767
PMCPMC7485372
OpenAlexW3033985764

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.